Disclosing biomarker results+B2:B5

0 SAR
Checkout

Overview

Prof. Dr. Kenjiro Ono and Prof. Dr. Jens Wiltfang discuss on the clinical importance of
disclosing biomarker results to patients with mild cognitive impairment.

This Class for

  • Physician
  • Resident / Fellow

What I will learn?

  • 1. To evaluate the impact of disclosing biomarker results on the clinical management of patients with mild cognitive impairment.
    2. Explain the shift in Alzheimer’s diagnosis from a primarily clinical approach to one that incorporates pathological and biomarker-based methods.





    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
    24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
    For further information, please contact:
    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com


    PP-AD-SA-0070

Related Classes